Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism

Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels...

Full description

Saved in:
Bibliographic Details
Published in:Canadian respiratory journal 2022-04, Vol.2022, p.6619331-9
Main Authors: Hao, Fangfang, Chen, Jinliang, Wu, Jinnan, Ge, Xin, Lv, Xuedong, Zhang, Dongmei, Chen, Jianrong
Format: Article
Language:English
Subjects:
Cancer therapies
Carcinoembryonic Antigen - metabolism
Carcinoma, Non-Small-Cell Lung
Cardiovascular disease
Care and treatment
CEA (Oncology)
Cell receptors
Cholesterol
Comparative analysis
Development and progression
Diagnosis
Drug dosages
Health aspects
Health care
Heart
High density lipoprotein
Hormone replacement therapy
Hospital patients
Hospitals
Humans
Lectins
Lipid Metabolism
Lipids
Lipoproteins
Lipoproteins, LDL - metabolism
Low density lipoproteins
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms
Measurement
Medical prognosis
Metabolism
Metastasis
Normal distribution
Physiological aspects
Scavenger Receptors, Class E - metabolism
Serodiagnosis
Signal transduction
Triglycerides
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413
cites cdi_FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413
container_end_page 9
container_issue
container_start_page 6619331
container_title Canadian respiratory journal
container_volume 2022
creator Hao, Fangfang
Chen, Jinliang
Wu, Jinnan
Ge, Xin
Lv, Xuedong
Zhang, Dongmei
Chen, Jianrong
description Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed. Results. Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher (p 
doi_str_mv 10.1155/2022/6619331
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e9a8706f52fe470c9c9b767df9881927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A814202625</galeid><doaj_id>oai_doaj_org_article_e9a8706f52fe470c9c9b767df9881927</doaj_id><sourcerecordid>A814202625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413</originalsourceid><addsrcrecordid>eNp9ku9r1DAch4sobp6-87UUByJotyTNzzfCOKYenE6Ygu9CmqZ3OdqkS1qn_73p7px3MqQvWtLn-6T59JNlzyE4hZCQMwQQOqMUirKED7JjKCAtGMLkYXqGghcIYXiUPYlxAwCGTODH2VFJMBaEsOOsv_jZBxOj9S73TX5lwtjlcXn5vYC5dfkXNVjjhpjf2GGdf_auuOpU2xZz07b5cnSrfK6cNiFXrs4XiZv7EEybppLvdmZpe1vnn8ygKt_a2D3NHjWqjebZ7j7Lvr2_-Dr_WCwvPyzm58tC01IMBRe8Eg1VAItG1XVZcVArno4qakRKqikBNakAE4wLqkqktQYKG1RVhmKCYTnLFltv7dVG9sF2KvySXll5u-DDSqowWN0aaYTiDNCGoMZgBrTQomKU1Y3gHArEkuvd1tWPVWdqnRIJqj2QHr5xdi1X_ocUADLMp495vRMEfz2aOMjORp0yVM74MUpECUacMlwm9OQfdOPH4FJUE1UKABDFf6mVSgewrvFpXz1J5TmHOHWCpphm2ct7KN3ba7kPnd4Dpas2ndXemcam9QPrq72BtVHtsI6-Had_Hg_Bt1tQBx9jMM1dYhDIqbty6q7cdTfhL_ZTvoP_lDUBb7bA2rpa3dj_634Db17xPw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2653900264</pqid></control><display><type>article</type><title>Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>Hao, Fangfang ; Chen, Jinliang ; Wu, Jinnan ; Ge, Xin ; Lv, Xuedong ; Zhang, Dongmei ; Chen, Jianrong</creator><contributor>Melani, Andrea S. ; Andrea S Melani</contributor><creatorcontrib>Hao, Fangfang ; Chen, Jinliang ; Wu, Jinnan ; Ge, Xin ; Lv, Xuedong ; Zhang, Dongmei ; Chen, Jianrong ; Melani, Andrea S. ; Andrea S Melani</creatorcontrib><description>Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed. Results. Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher (p &lt; 0.05), while the expression level of high-density lipoprotein was lower (p &lt; 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein (r = 0.72, p &lt; 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage (p &lt; 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, p &lt; 0.01, 95% CI: 0.989–1.000). Conclusion. sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.</description><identifier>ISSN: 1198-2241</identifier><identifier>EISSN: 1916-7245</identifier><identifier>DOI: 10.1155/2022/6619331</identifier><identifier>PMID: 35449557</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Cancer therapies ; Carcinoembryonic Antigen - metabolism ; Carcinoma, Non-Small-Cell Lung ; Cardiovascular disease ; Care and treatment ; CEA (Oncology) ; Cell receptors ; Cholesterol ; Comparative analysis ; Development and progression ; Diagnosis ; Drug dosages ; Health aspects ; Health care ; Heart ; High density lipoprotein ; Hormone replacement therapy ; Hospital patients ; Hospitals ; Humans ; Lectins ; Lipid Metabolism ; Lipids ; Lipoproteins ; Lipoproteins, LDL - metabolism ; Low density lipoproteins ; Lung cancer ; Lung cancer, Non-small cell ; Lung Neoplasms ; Measurement ; Medical prognosis ; Metabolism ; Metastasis ; Normal distribution ; Physiological aspects ; Scavenger Receptors, Class E - metabolism ; Serodiagnosis ; Signal transduction ; Triglycerides ; Tumors</subject><ispartof>Canadian respiratory journal, 2022-04, Vol.2022, p.6619331-9</ispartof><rights>Copyright © 2022 Fangfang Hao et al.</rights><rights>COPYRIGHT 2022 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2022 Fangfang Hao et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Fangfang Hao et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413</citedby><cites>FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413</cites><orcidid>0000-0003-2788-1226 ; 0000-0002-0880-8907 ; 0000-0001-9379-6033 ; 0000-0002-4132-7363</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2653900264/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2653900264?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35449557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Melani, Andrea S.</contributor><contributor>Andrea S Melani</contributor><creatorcontrib>Hao, Fangfang</creatorcontrib><creatorcontrib>Chen, Jinliang</creatorcontrib><creatorcontrib>Wu, Jinnan</creatorcontrib><creatorcontrib>Ge, Xin</creatorcontrib><creatorcontrib>Lv, Xuedong</creatorcontrib><creatorcontrib>Zhang, Dongmei</creatorcontrib><creatorcontrib>Chen, Jianrong</creatorcontrib><title>Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism</title><title>Canadian respiratory journal</title><addtitle>Can Respir J</addtitle><description>Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed. Results. Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher (p &lt; 0.05), while the expression level of high-density lipoprotein was lower (p &lt; 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein (r = 0.72, p &lt; 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage (p &lt; 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, p &lt; 0.01, 95% CI: 0.989–1.000). Conclusion. sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.</description><subject>Cancer therapies</subject><subject>Carcinoembryonic Antigen - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>CEA (Oncology)</subject><subject>Cell receptors</subject><subject>Cholesterol</subject><subject>Comparative analysis</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Drug dosages</subject><subject>Health aspects</subject><subject>Health care</subject><subject>Heart</subject><subject>High density lipoprotein</subject><subject>Hormone replacement therapy</subject><subject>Hospital patients</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lectins</subject><subject>Lipid Metabolism</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Low density lipoproteins</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung Neoplasms</subject><subject>Measurement</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Normal distribution</subject><subject>Physiological aspects</subject><subject>Scavenger Receptors, Class E - metabolism</subject><subject>Serodiagnosis</subject><subject>Signal transduction</subject><subject>Triglycerides</subject><subject>Tumors</subject><issn>1198-2241</issn><issn>1916-7245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ku9r1DAch4sobp6-87UUByJotyTNzzfCOKYenE6Ygu9CmqZ3OdqkS1qn_73p7px3MqQvWtLn-6T59JNlzyE4hZCQMwQQOqMUirKED7JjKCAtGMLkYXqGghcIYXiUPYlxAwCGTODH2VFJMBaEsOOsv_jZBxOj9S73TX5lwtjlcXn5vYC5dfkXNVjjhpjf2GGdf_auuOpU2xZz07b5cnSrfK6cNiFXrs4XiZv7EEybppLvdmZpe1vnn8ygKt_a2D3NHjWqjebZ7j7Lvr2_-Dr_WCwvPyzm58tC01IMBRe8Eg1VAItG1XVZcVArno4qakRKqikBNakAE4wLqkqktQYKG1RVhmKCYTnLFltv7dVG9sF2KvySXll5u-DDSqowWN0aaYTiDNCGoMZgBrTQomKU1Y3gHArEkuvd1tWPVWdqnRIJqj2QHr5xdi1X_ocUADLMp495vRMEfz2aOMjORp0yVM74MUpECUacMlwm9OQfdOPH4FJUE1UKABDFf6mVSgewrvFpXz1J5TmHOHWCpphm2ct7KN3ba7kPnd4Dpas2ndXemcam9QPrq72BtVHtsI6-Had_Hg_Bt1tQBx9jMM1dYhDIqbty6q7cdTfhL_ZTvoP_lDUBb7bA2rpa3dj_634Db17xPw</recordid><startdate>20220411</startdate><enddate>20220411</enddate><creator>Hao, Fangfang</creator><creator>Chen, Jinliang</creator><creator>Wu, Jinnan</creator><creator>Ge, Xin</creator><creator>Lv, Xuedong</creator><creator>Zhang, Dongmei</creator><creator>Chen, Jianrong</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2788-1226</orcidid><orcidid>https://orcid.org/0000-0002-0880-8907</orcidid><orcidid>https://orcid.org/0000-0001-9379-6033</orcidid><orcidid>https://orcid.org/0000-0002-4132-7363</orcidid></search><sort><creationdate>20220411</creationdate><title>Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism</title><author>Hao, Fangfang ; Chen, Jinliang ; Wu, Jinnan ; Ge, Xin ; Lv, Xuedong ; Zhang, Dongmei ; Chen, Jianrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer therapies</topic><topic>Carcinoembryonic Antigen - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>CEA (Oncology)</topic><topic>Cell receptors</topic><topic>Cholesterol</topic><topic>Comparative analysis</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Drug dosages</topic><topic>Health aspects</topic><topic>Health care</topic><topic>Heart</topic><topic>High density lipoprotein</topic><topic>Hormone replacement therapy</topic><topic>Hospital patients</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lectins</topic><topic>Lipid Metabolism</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Low density lipoproteins</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung Neoplasms</topic><topic>Measurement</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Normal distribution</topic><topic>Physiological aspects</topic><topic>Scavenger Receptors, Class E - metabolism</topic><topic>Serodiagnosis</topic><topic>Signal transduction</topic><topic>Triglycerides</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hao, Fangfang</creatorcontrib><creatorcontrib>Chen, Jinliang</creatorcontrib><creatorcontrib>Wu, Jinnan</creatorcontrib><creatorcontrib>Ge, Xin</creatorcontrib><creatorcontrib>Lv, Xuedong</creatorcontrib><creatorcontrib>Zhang, Dongmei</creatorcontrib><creatorcontrib>Chen, Jianrong</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business &amp; Current Affairs Database</collection><collection>Canadian Business &amp; Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Canadian respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hao, Fangfang</au><au>Chen, Jinliang</au><au>Wu, Jinnan</au><au>Ge, Xin</au><au>Lv, Xuedong</au><au>Zhang, Dongmei</au><au>Chen, Jianrong</au><au>Melani, Andrea S.</au><au>Andrea S Melani</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism</atitle><jtitle>Canadian respiratory journal</jtitle><addtitle>Can Respir J</addtitle><date>2022-04-11</date><risdate>2022</risdate><volume>2022</volume><spage>6619331</spage><epage>9</epage><pages>6619331-9</pages><issn>1198-2241</issn><eissn>1916-7245</eissn><abstract>Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed. Results. Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher (p &lt; 0.05), while the expression level of high-density lipoprotein was lower (p &lt; 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein (r = 0.72, p &lt; 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage (p &lt; 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, p &lt; 0.01, 95% CI: 0.989–1.000). Conclusion. sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>35449557</pmid><doi>10.1155/2022/6619331</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2788-1226</orcidid><orcidid>https://orcid.org/0000-0002-0880-8907</orcidid><orcidid>https://orcid.org/0000-0001-9379-6033</orcidid><orcidid>https://orcid.org/0000-0002-4132-7363</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-2241
ispartof Canadian respiratory journal, 2022-04, Vol.2022, p.6619331-9
issn 1198-2241
1916-7245
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e9a8706f52fe470c9c9b767df9881927
source Open Access: PubMed Central; Publicly Available Content Database; Wiley Open Access
subjects Cancer therapies
Carcinoembryonic Antigen - metabolism
Carcinoma, Non-Small-Cell Lung
Cardiovascular disease
Care and treatment
CEA (Oncology)
Cell receptors
Cholesterol
Comparative analysis
Development and progression
Diagnosis
Drug dosages
Health aspects
Health care
Heart
High density lipoprotein
Hormone replacement therapy
Hospital patients
Hospitals
Humans
Lectins
Lipid Metabolism
Lipids
Lipoproteins
Lipoproteins, LDL - metabolism
Low density lipoproteins
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms
Measurement
Medical prognosis
Metabolism
Metastasis
Normal distribution
Physiological aspects
Scavenger Receptors, Class E - metabolism
Serodiagnosis
Signal transduction
Triglycerides
Tumors
title Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A32%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20Serum%20sLOX-1%20in%20Patients%20with%20Non-Small-Cell%20Lung%20Cancer%20and%20Its%20Correlation%20with%20Lipid%20Metabolism&rft.jtitle=Canadian%20respiratory%20journal&rft.au=Hao,%20Fangfang&rft.date=2022-04-11&rft.volume=2022&rft.spage=6619331&rft.epage=9&rft.pages=6619331-9&rft.issn=1198-2241&rft.eissn=1916-7245&rft_id=info:doi/10.1155/2022/6619331&rft_dat=%3Cgale_doaj_%3EA814202625%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c639t-898b9f6a049fadd3b80da80229d2536c650d5b0797896a32ccc0a4e2bbe645413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2653900264&rft_id=info:pmid/35449557&rft_galeid=A814202625&rfr_iscdi=true